Amgen supports Biotechnology Industry Organization’s opposition to COVID-19 vaccine intellectual property waivers
In 2021, Amgen CEO Bob Bradway joined other biotechnology industry leaders in supporting the Biotechnology Industry Association’s declaration recognizing the industry’s role in expanding access to COVID-19 (coronavirus) vaccines while opposing intellectual property (IP) waivers. The association emphasized the importance of biotechnology companies working with governments to support distribution readiness and eliminating certain trade barriers. The declaration also warned that IP waivers may deter future investment and curtail biopharmaceutical innovation.
COVID|Competition|New Activity|ESGIn response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.
Lorem Ipsum text header Report Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.
Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.